Tag: Compounding pharmacy

In clinical trials, the active ingredient tirzepatide demonstrated remarkable efficacy for weight loss, with participants achieving up to 22.5% body weight reduction. The question, however, is: does compounded tirzepatide work with the same reliability and safety? The answer involves understanding significant differences in regulation, quality, and formulation.

Betahistine is widely prescribed for Meniere's disease and vertigo in more than 80 countries worldwide, yet its FDA approval was rescinded in the US during the 1970s due to a lack of substantial evidence of efficacy. This withdrawal was based on a reevaluation of clinical data, leaving many patients wondering why is betahistine no longer available in the United States.

While betahistine is widely used in more than 80 countries for managing vertigo, it has not been commercially available in the United States for decades. As such, there is no standardized US brand name for betahistine on the commercial market, though it may be obtained through specific channels.

While the generic name for Kybella is deoxycholic acid, no *FDA-approved* generic version of Kybella is currently available on the market. Instead, some clinics offer compounded deoxycholic acid as an alternative treatment for submental fat, raising important considerations regarding safety, efficacy, and cost.

According to the FDA, compounded drugs, including those containing semaglutide, do not undergo the rigorous premarket review for safety and effectiveness that approved drugs do. The compounded formulation known as **Semaglutide with B12 and Glycine** is a medication created by specialized pharmacies, not the original manufacturers, to aid in weight management and address some potential side effects of semaglutide.

Contrary to some circulating rumors, Zepbound's manufacturer, Eli Lilly, is not discontinuing the popular weight-loss medication. Instead, recent patient-facing changes are related to a mix of resolved national shortages, new FDA regulations on compounded alternatives, and shifts in insurance coverage by some pharmacy benefit managers.

Musely, as a telehealth platform, is not directly approved by the FDA because it is a service, not a product. However, its operation is structured to comply with FDA regulations by using board-certified dermatologists and partnering with state-licensed, FDA-compliant compounding pharmacies. This unique model ensures access to customized, prescription-strength skincare and medication.

While oral tablets are the most common antibiotic form, some specialized situations require alternative delivery methods. For those with specific medical needs, the question "Are there any antibiotic suppositories?" is highly relevant, and the answer involves understanding both commercially available and compounded options for targeted treatment.

In 2000, Janssen Pharmaceutica voluntarily stopped marketing the human version of cisapride (Propulsid) in the United States after hundreds of adverse event reports, including deaths, were linked to the drug's use. The key question, "Is cisapride still available?", now has a complex answer depending on the patient and species in question.

The anti-vertigo medication betahistine, widely prescribed in over 80 countries, is not commercially available in the United States. Patients asking, "**Can you get betahistine in the USA?**", discover that its journey began with a brief FDA approval that was later withdrawn due to insufficient evidence of efficacy. However, the medication is still accessible through specialized compounding pharmacies with a doctor's prescription.